Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
This trial is active, not recruiting.
|Condition||age-related macular degeneration|
|Phase||phase 2/phase 3|
|Sponsor||Canadian Retinal Trials Group|
|Collaborator||University of British Columbia|
|Start date||January 2004|
|End date||March 2008|
|Trial size||120 participants|
|Trial identifier||NCT00148551, 01 (C03 - 0236)|
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
Changes in visual acuity from baseline.
Change in lesion characteristics from baseline.
Male or female participants at least 50 years old.
Inclusion Criteria: - Individuals with predominantly classic, subfoveal CNV secondary to AMD. - No previous PDT Treatment in study eye. Exclusion Criteria: - CNV from conditions, other than AMD. - Other disease that could be responsible for decreased vision.
|Official title||Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.|
|Description||This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.|
Call for more information